Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study...